Alfacell Corporation is a biopharmaceutical company engaged in developing drugs for the treatment of cancer and other pathological conditions. It is the first company to develop a biopharmaceutical product candidate that works similar to RNA interference (RNAi) through late-stage clinical trials. The major product candidate of the company is ONCONASE, an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. ONCONASE is currently going through the third phase of clinical trials for the treatment of different varieties of cancer.
Alfacell Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.
Scope
- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
For more information please visit :
http://www.aarkstore.com/reports/Alfacell-Corporation-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-20146.html |
